Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | The impact of the clinical trial of venetoclax (ABT-199) and obinutuzumab in CLL

Thomas Kipps • 4 Dec 2015
ASH 2015
Chronic Lymphocytic Leukemia Antibodies Obinutuzumab Venetoclax

Thomas Kipps, MD from the University of California, San Diego, CA, discussed the impact of the clinical trial of venetoclax (ABT-199) with obinutuzumab in the treatment landscape chronic lymphocytic leukemia (CLL).

More from Thomas Kipps

1:28
A long-term analysis of lenalidomide and rituximab for the treatment of CLL
Thomas Kipps • 11 Dec 2023
1:35
Ven-based regimens for R/R CLL and considering an MRD-guided strategy
Thomas Kipps • 11 Dec 2023
1:18
The use of genomics to help select treatment in CLL
Thomas Kipps • 9 Jun 2023
2:12
Understanding and overcoming resistance to BTK and BCL-2 inhibitors in CLL
Thomas Kipps • 9 Jun 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals